-
Je něco špatně v tomto záznamu ?
Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma
J. Skoda, M. Hermanova, T. Loja, P. Nemec, J. Neradil, P. Karasek, R. Veselska,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2006
Free Medical Journals
od 2006
Public Library of Science (PLoS)
od 2006
PubMed Central
od 2006
Europe PubMed Central
od 2006
ProQuest Central
od 2006-12-01
Open Access Digital Library
od 2006-01-01
Open Access Digital Library
od 2006-10-01
Open Access Digital Library
od 2006-01-01
Medline Complete (EBSCOhost)
od 2008-01-01
Nursing & Allied Health Database (ProQuest)
od 2006-12-01
Health & Medicine (ProQuest)
od 2006-12-01
Public Health Database (ProQuest)
od 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
od 2006
- MeSH
- adenokarcinom diagnóza metabolismus MeSH
- adhezní molekula epiteliálních buněk metabolismus MeSH
- antigen AC133 metabolismus MeSH
- antigen CD24 metabolismus MeSH
- antigeny CD44 metabolismus MeSH
- kmenové buňky metabolismus MeSH
- kultivované buňky MeSH
- kvantitativní polymerázová řetězová reakce MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery MeSH
- nádory slinivky břišní diagnóza metabolismus MeSH
- nestin metabolismus MeSH
- prognóza MeSH
- průtoková cytometrie MeSH
- regulace genové exprese u nádorů MeSH
- senioři MeSH
- transkriptom MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Its dismal prognosis is often attributed to the presence of cancer stem cells (CSCs) that have been identified in PDAC using various markers. However, the co-expression of all of these markers has not yet been evaluated. Furthermore, studies that compare the expression levels of CSC markers in PDAC tumor samples and in cell lines derived directly from those tumors are lacking. Here, we analyzed the expression of putative CSC markers-CD24, CD44, epithelial cell adhesion molecule (EpCAM), CD133, and nestin-by immunofluorescence, flow cytometry and quantitative PCR in 3 PDAC-derived cell lines and by immunohistochemistry in 3 corresponding tumor samples. We showed high expression of the examined CSC markers among all of the cell lines and tumor samples, with the exception of CD24 and CD44, which were enriched under in vitro conditions compared with tumor tissues. The proportions of cells positive for the remaining markers were comparable to those detected in the corresponding tumors. Co-expression analysis using flow cytometry revealed that CD24+/CD44+/EpCAM+/CD133+ cells represented a significant population of the cells (range, 43 to 72%) among the cell lines. The highest proportion of CD24+/CD44+/EpCAM+/CD133+ cells was detected in the cell line derived from the tumor of a patient with the shortest survival. Using gene expression profiling, we further identified the specific pro-tumorigenic expression profile of this cell line compared with the profiles of the other two cell lines. Together, CD24+/CD44+/EpCAM+/CD133+ cells are present in PDAC cell lines derived from primary tumors, and their increased proportion corresponds with a pro-tumorigenic gene expression profile.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031587
- 003
- CZ-PrNML
- 005
- 20171025123047.0
- 007
- ta
- 008
- 171025s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0159255 $2 doi
- 035 __
- $a (PubMed)27414409
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Skoda, Jan $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 245 10
- $a Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma / $c J. Skoda, M. Hermanova, T. Loja, P. Nemec, J. Neradil, P. Karasek, R. Veselska,
- 520 9_
- $a Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Its dismal prognosis is often attributed to the presence of cancer stem cells (CSCs) that have been identified in PDAC using various markers. However, the co-expression of all of these markers has not yet been evaluated. Furthermore, studies that compare the expression levels of CSC markers in PDAC tumor samples and in cell lines derived directly from those tumors are lacking. Here, we analyzed the expression of putative CSC markers-CD24, CD44, epithelial cell adhesion molecule (EpCAM), CD133, and nestin-by immunofluorescence, flow cytometry and quantitative PCR in 3 PDAC-derived cell lines and by immunohistochemistry in 3 corresponding tumor samples. We showed high expression of the examined CSC markers among all of the cell lines and tumor samples, with the exception of CD24 and CD44, which were enriched under in vitro conditions compared with tumor tissues. The proportions of cells positive for the remaining markers were comparable to those detected in the corresponding tumors. Co-expression analysis using flow cytometry revealed that CD24+/CD44+/EpCAM+/CD133+ cells represented a significant population of the cells (range, 43 to 72%) among the cell lines. The highest proportion of CD24+/CD44+/EpCAM+/CD133+ cells was detected in the cell line derived from the tumor of a patient with the shortest survival. Using gene expression profiling, we further identified the specific pro-tumorigenic expression profile of this cell line compared with the profiles of the other two cell lines. Together, CD24+/CD44+/EpCAM+/CD133+ cells are present in PDAC cell lines derived from primary tumors, and their increased proportion corresponds with a pro-tumorigenic gene expression profile.
- 650 _2
- $a antigen AC133 $x metabolismus $7 D000071916
- 650 _2
- $a adenokarcinom $x diagnóza $x metabolismus $7 D000230
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antigen CD24 $x metabolismus $7 D051927
- 650 _2
- $a antigeny CD44 $x metabolismus $7 D018960
- 650 _2
- $a nádorové biomarkery $7 D014408
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a adhezní molekula epiteliálních buněk $x metabolismus $7 D000071858
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nestin $x metabolismus $7 D064231
- 650 _2
- $a nádory slinivky břišní $x diagnóza $x metabolismus $7 D010190
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a kvantitativní polymerázová řetězová reakce $7 D060888
- 650 _2
- $a kmenové buňky $x metabolismus $7 D013234
- 650 _2
- $a transkriptom $7 D059467
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hermanova, Marketa $u 1st Department of Pathological Anatomy, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Loja, Tomas $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Nemec, Pavel $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Neradil, Jakub $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Karasek, Petr $u Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
- 700 1_
- $a Veselska, Renata $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 7 (2016), s. e0159255
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27414409 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171025123129 $b ABA008
- 999 __
- $a ok $b bmc $g 1255180 $s 992614
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 11 $c 7 $d e0159255 $e 20160714 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20171025